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ABSTRACT
Purpose Granulocyte colony-stimulating factor (G-CSF) is
often used in cancer patients receiving cytotoxic drugs to
prevent or reduce high grade neutropenia. We propose a
pharmacokinetic/pharmacodynamic model to describe
myelotoxicity in both G-CSF treated and non-treated patients
that shall increase our understanding of G-CSF effects.
Methods The model was built from absolute neutrophil counts
(ANC) obtained in 375 carboplatin-treated patients, 47 of whom
received G-CSF. It includes some prior information on G-CSF
taken from the literature. Simulations were performed to under-
stand differences in G-CSF effects and explore the impact of G-CSF
formulation.
Results Our model well described the data in all patients. Model
simulations showed that G-CSF was not as beneficial as expected in
some patients. Furthermore, a longer and stronger effect was
observed for the pegylated formulation in comparison with the
daily standard formulation even if the latter was given for 11
consecutive days.
Conclusions The proposed model allows a mechanistic inter-
pretation of G-CSF effects on ANC and raises the question of a
systematic beneficial effect of G-CSF treatment. Other studies
are needed to confirm these findings and help identifying patients
for whom G-CSF is beneficial.
KEY WORDS chemotherapy . G-CSF . myelotoxicity .
neutropenia . pharmacokinetic/pharmacodynamic (PK/PD)
modeling
ABBREVIATIONS
Abs1 Absorption compartment for filgrastim/lenograstim
Abs2 Absorption compartment for pegfilgrastim
ANC Absolute neutrophil count
Base Baseline level of absolute neutrophil count
Ccarbo Ultrafiltrable circulating (plasma) concentration of
carboplatin
Cu Free circulating concentration controlling G-CSF
effects on bone marrow, calculated as the sum of
non-pegylated and pegylated G-CSF free circulat-
ing (serum) concentrations
Circ Circulating mature neutrophil count (=ANC)
Emax1 Maximal effect of non-pegylated or pegylated G-
CSF on proliferation
Emax2 Maximal effect of non-pegylated or pegylated G-
CSF on maturation
EC501 Value of Cu eliciting 50% of the maximal effect on
proliferation
EC502 Value of Cu eliciting 50% of the maximal effect on
maturation
F1(F2) Absolute bioavailability of
filgrastim/lenograstim(pegfilgrastim) after subcutane-
ous administration (which, in the model, is taking into
account via the apparent volume of distribution)
G-CSF Granulocyte colony-stimulating factor
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k Transit rate constant between compartments of
granulopoiesis (function of Cu)
k ¼ ktr  1þ Emax2CuEC502þCu
  
ka1(2) Absorption rate constant for filgrastim/lenograstim
(pegfilgrastim)
kcirc Rate constant of elimination of neutrophils from
the systemic blood circulation
KD Dissociation constant of RC complex (= koff /kon)
kel1 Rate constant for the linear, non-specific elimina-
tion of endogenous G-CSF and
filgrastim/lenograstim
kel2 Rate constant for the linear, non-specific elimina-
tion of pegfilgrastim
kGCSF Rate constant of endogenous G-CSF production
kint Rate constant for non-pegylated or pegylated G-
CSF elimination after binding to receptors and
internalization
kprol Proliferation rate constant
ktr “Virtual” transit rate constant when Cu=0 (cf. k)
MTT Mean transit time for maturing precursors in bone
marrow MTT ¼ 4=ktr  1þ Emax2CuEC502þC u
  
PK Pharmacokinetic(s)
PK/PD Pharmacokinetic(s)/pharmacodynamic(s)
Prol Stem cell and progenitor cell count (i.e. prolifera-
tive cells) in bone marrow
R Concentration in G-CSF receptors present on cir-
culating neutrophils
RC Concentration in bound G-CSF complex
(pegylated and non-pegylated G-CSF)
Rmax Maximal amount of receptors involved in
nonlinear, specific clearance of pegylated and on-
pegylated G-CSF (=R+RC)
RSE Relative standard error
Slope Sensitivity to carboplatin myelotoxicity
Transit1,2,3 Maturating granulocyte precursor count in transit
compartments 1, 2 and 3, respectively
VDa1(2) Apparent volume of distribution of G-CSF
(pegylated G-CSF) after subcutaneous administra-
tion of filgrastim/lenograstim (pegfilgrastim)
(VD1(2)/F1(2))
x Proportionality constant for the amount of G-CSF
receptors per cell
INTRODUCTION
Because of the risk of infection, chemotherapy-induced high
grade neutropenia is a major concern and requires dose
reduction, delays or discontinuation in anticancer drug ad-
ministration, which may compromise clinical outcome espe-
cially in curative regimens (1). In this respect, granulocyte
colony-stimulating factor (G-CSF) is often administered to
patients receiving cytotoxic drugs in order to prevent or
reduce high grade neutropenia which is closely related to
febrile neutropenia (2–5).
Exogenous G-CSF reproduces the physiological effect of its
endogenous counterpart, that is to say it increases the prolif-
eration of granulocyte progenitors, reduces their maturation
time, stimulates the release of precursors from the bone mar-
row and enhances the survival and function of mature neu-
trophils, resulting in an increase in absolute neutrophil counts
(ANC) (6,7). However, it must be noted that G-CSF only
reduces the occurrence of chemotherapy-associated febrile
neutropenia (3–5,8) and cannot prevent febrile neutropenia
or infections in all patients. Different formulations of G-CSF
are available on the market, i.e., daily formulations (e.g.
filgrastim, lenograstim) as well as a pegylated once-per-cycle
formulation (pegfilgrastim). The current guidelines do not
recommend to use one formulation versus another (8,9)
but more and more authors suggest that pegfilgrastim
would be more effective than the daily forms, most
likely due to a better compliance (4,5,10,11). Pegfilgrastim
is a sustained-duration form of filgrastim to which a
20 kDa polyethylene glycol molecule is covalently bound
to the N-terminal methionine residue. It results that
pegfilgrastim has a higher molecular weight (38.8 kDa)
than filgrastim (18.8 kDa) and a much higher hydrodynamic
radius (12). This leads to a dramatically lower renal clearance
of pegfilgrastim compared to filgrastim, with an enhanced
serum terminal half-life explaining the sustained duration
of effect and the once-per-cycle administration (13). These
two proteins share the same binding domain for G-CSF
receptor and therefore initiate the same signaling, resulting
in the identical mechanism of action.
Pharmacokinetic-pharmacodynamic (PK/PD) modeling
has proved very useful to describe the neutrophil time-
course during chemotherapy and predict at-risk neutrope-
nia. Several PK/PD models have been proposed in the past
decades (see (14–16) for reviews) but the most popular stays
the one of Friberg et al. (17) proposed in 2002. This semi-
mechanistic model uses five compartments to describe the
proliferation and maturation of progenitor and precursor
cells in the bone marrow as well as the myelotoxicity of
anticancer drugs. In this model, the negative feedback mech-
anism regulating the proliferation of progenitor cells to
maintain physiological ANC levels is described using an
empirical power function of ANC (i.e. baseline ANC before
the start of chemotherapy divided by the current ANC value,
the whole raised to a power γ). Actually, this negative feed-
back is described as corresponding to the effect of endoge-
nous growth hormones, mainly G-CSF. Since G-CSF has
also an impact on the maturation of precursors, a recent
improvement of Friberg’s model has been proposed in the
case of docetaxel administration (18). More precisely, the
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power function of ANC ratio has been incorporated not only
at the proliferation level but also at the maturation level,
allowing an acceleration of maturation rate when ANC are
too low.
Such empirical models are not adapted to describe the
effect of exogenous G-CSF and patients receiving exogenous
G-CSF are generally excluded from the PK/PD analysis.
Because G-CSF is given to patients that are potentially more
sensitive to anticancer drugs, the exclusion of such patients
may introduce a selection bias, and a model capable to de-
scribe neutrophil time-course in case of G-CSF administration
is thus highly desirable. Some rough adaptations of Friberg’s
model have been proposed that incorporate G-CSF treatment
as a covariate in the model (19–21). However, the adjunction
of G-CSF as a “yes/no” covariate only provides an on/off
switch and does not allow the prediction of more subtle
adjustments in dose, dosing time and duration of G-CSF
treatment. Other, more mechanistic models have been
developed for that purpose (15,22–33) but some have been
validated in very few cancer patients (26) or in healthy subjects
only (22–24,28,29,31,32) or were not very physiological
(15,30).
The objective of our work was thus to adapt the widely
used Friberg’s model to include G-CSF as the driving force
for the negative feedback, making the model more physio-
logical and widening its application to every cancer patient
irrespective of potential G-CSF treatment during their che-
motherapy. Furthermore, such a model shall allow a better
understanding of G-CSF effects in cancer patients. Indeed,
in our data set, some patients showed unexpectedly low nadir
despite G-CSF administration and a relatively high ANC
baseline (Fig. 1). Recall that G-CSF has two main effects: it
stimulates stem cell proliferation and accelerates maturation
time. It is thus possible that an acceleration in maturation
time by G-CSF concomitant with a depletion of progenitor
cell compartment due to anticancer drug toxicity is not
beneficial for the patient: in other terms, G-CSF treatment
may not result in a lower and/or shorter neutropenia com-
pared to the absence of G-CSF treatment. The data set used
for analysis has been previously analyzed with the Friberg’s
model after removing the data of patients receiving G-CSF
(34). Here, we analyze all data together, accounting for
differences in G-CSF formulations (pegylated and daily
forms). The model was used to explore the differences be-
tween formulations of G-CSF in terms of efficacy.
MATERIALS AND METHODS
Study Design
Three hundred and seventy-five cancer patients with various
malignant tumors, receiving carboplatin as part of established
regimens as monochemotherapy or in combination with dif-
ferent other cytotoxic drugs were recruited in thirteen centers
(Supplementary Material 1). Further details are given in (34).
Among these patients, 47 were given G-CSF subcutaneous-
ly either as a daily formulation (filgrastim (Neupogen®) or
lenograstim (Granocyte®) at 5 μg/kg/day; N=31) or as
pegfilgrastim (Neulasta® at 6 mg; N=17). G-CSF could be
administered on cycle 1 and/or on cycle 2. All patients who
received G-CSF at cycle 2 had experienced a 3/4-grade
neutropenia at cycle 1. The rational for G-CSF administra-
tion at cycle 1 was more variable and depended on the
clinician’s expertise (age, previous chemotherapy, pathologi-
cal status…). In all 47 patients receiving G-CSF, G-CSF was
given at least 1 day after the administration of carboplatin,
except for three patients (G-CSF administered the same day).
Regarding other cytotoxic drug, G-CSF was given before the
end of the etoposide treatment for three additional patients.
Pegfilgrastim
Filgrastim
(5 days)
a b99
Fig. 1 Observed data for two
patients who experienced high
grade neutropenia despite G-CSF
treatment during their
chemotherapy. Carboplatin
administrations are indicated by
vertical arrows (at day 0 and 54 for
patient a, at day 0 and day 35 for
patient b). Pegfilgrastim was given
subcutaneously to patient A at day
4 (6 mg), and filgrastim was given
subcutaneously to patient b at day
5 during 5 days (5 μg/kg/day) and
at day 40 during 5 days (5 μg/kg/
day).
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The protocol was approved by the ethical committee of
Toulouse and informed written consent was obtained
from each patient. The clinical and biological charac-
teristics of individuals receiving or not G-CSF are
displayed in Table I and were not significantly different
between the two groups.
Carboplatin was given as a single intravenous infusion over
30 or 60 min at the beginning of each cycle with a theoretical
intercycle period of 3 weeks. The intravenous doses of
carboplatin were adjusted according to the body surface area
of the patient or his/her predicted carboplatin clearance,
depending on the centers and the regimen. Four blood
Table I Characteristics of the 375
Patients
a Calculated according to the Du-
bois equation
bMedian dose
Characteristic Mean [Minimum – Maximum] for continuous variables
Number (percentage) for categorical variables
Patients without G-CSF Patients with G-CSF
Total no. of patients 328 47
Sex
No. Females 247 (75.3%) 27 (57.4%)
No. Males 81 (24.7%) 20 (42.6%)
Dose of carboplatin (mg) 547 [170–1200] 531 [210–955]
Body Surface Areaa (m2) 1.7 [1.3–2.3] 1.7 [1.4–2.4]
Weight (kg) 65 [40–137] 65 [40–123]
Height (cm) 164 [146–187] 165 [150–183]
Age (years) 60 [21–87] 60 [24–83]
Neutrophil baseline (× 109/L) 5.542 [1.357–25.370] 6.069 [1.750–13.120]
Primary tumor site
Ovary 146 (44.5%) 17 (36.2%)
Uterus 44 (13.4%) 1 (2.0%)
Lung 36 (11.0%) 6 (12.8%)
Soft tissues 24 (7.3%) 6 (12.8%)
Others 62 (18.9%) 17 (36.2%)
Unknown 16 (4.9%) 0
Previous chemotherapy
Yes 117 (35.7%) 21 (44.7%)
No 208 (63.4%) 26 (55.3%)
Unknown 3 (0.9%) 0
Corticosteroids
Yes 64 (19.5%) 15 (31.9%)
No 263 (80.2%) 32 (68.1%)
Unknown 1 (0.3%) 0
Concomitant chemotherapy
None 68 (20.7%) 4 (8.5%)
Paclitaxel 175 mg/m2 b 188 (57.3%) 13 (27.7%)
Etoposide 120 mg/m2 on days 1, 2, 3b 14 (4.3%) 14 (29.8%)
Gemcitabine 1,000 mg/m2 on days 1, 8b 19 (5.8%) 1 (2.1%)
Others (fluorouracil, docetaxel, vinorelbine,
trastuzumab, doxorubicin, topotecan,
fotemustine, vinblastine)
39 (11.9%) 15 (31.9%)
Performance status
0 129 (39.4%) 21 (44.7%)
1 147 (44.8%) 16 (34.0%)
2 34 (10.4%) 5 (10.6%)
3 9 (2.7%) 3 (6.4%)
Unknown 9 (2.7%) 2 (4.3%)
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samples were taken to measure carboplatin-ultrafiltrable plas-
ma concentrations during the first two cycles: before the start
of carboplatin infusion, 5 min before the end of the infusion
and at 1 and 4 h after the end of the infusion. Cell blood
counts were scheduled before chemotherapy and then weekly
during the intercycle period.
Population PK/PD Model
The population PK/PDmodel was built from the ANC data
obtained over the first two cycles in all patients receiving or
not G-CSF. Predictions of carboplatin individual PK param-
eters (POSTHOC values in NONMEM) were obtained
from a previous population PK analysis using the model
described in (35) for carboplatin-ultrafitrable plasma
concentrations.
Our population PK/PD model comprises two parts. The
first part describes the proliferation and maturation of pro-
genitor and precursor cells in the bone marrow and was
adapted from Friberg’s model (17). The other part describes
the pharmacokinetics of G-CSF and its effect on bonemarrow
progenitors and precursors and was adapted from a previous
model developed by Krzyzanski et al. (32) for endogenous and
exogenous G-CSF. Figure 2 gives a schematic representation
of the resulting PK/PD model, including further modifica-
tions that will be presented in the Results section. As in Friberg
et al. (17), five compartments were used for the first part of the
model. One proliferation compartment represents the stem
cells and the proliferating precursor cells in the bone marrow.
From this compartment, the cells move through three transit
compartments, mimicking the maturation in bone marrow, to
the blood circulation compartment. Cells are then eliminated
Prol Transit 1
Transit 
2
Transit 
3 Circ
k kk k
kprol
Slope x C carbo MTT kcirc
Abs2
R RC+
F2
kon
koff
kel1
kGCSF
kintka2
E max2
EC50 2
Emax1 
EC501
Subcutaneous 
daily G-CSF
Abs1
F1
Subcutaneous 
pegylated G-CSF
ka1 G-CSF
Peg
G-CSF
kel2
Fig. 2 PK/PD model describing the neutropenic effect of carboplatin with G-CSF-based feedback mechanism. The effect of G-CSF (pegylated or non-
pegylated form) on proliferation and maturation processes in bone marrow were assumed to be driven by the free circulating G-CSF concentration. Standard
Emax models were used for that purpose (see Supplementary Material 2 for more details). The G-CSF receptor complex RC in blood was assumed to be
pharmacologically inactive. Prol: proliferative cells in bone marrow; Transit: maturating granulocyte precursors in bone marrow; Circ: circulating mature
neutrophils; MTT: mean transit time for maturing precursors in bone marrow; Slope: sensitivity to carboplatin myelotoxicity; Ccarbo: ultrafiltrable plasma
concentration of carboplatin; kprol: proliferation rate constant; k: transit rate constant; kcirc: rate constant of elimination of neutrophils from the systemic
circulation; Abs1: absorption compartment for filgrastim/lenograstim; Abs2: absorption compartment for pegfilgrastim; F1(F2): bioavailaility of filgrastim/
lenograstim(pegfilgrastim); Cu: free circulating concentration controlling G-CSF effects on bone marrow, calculated as the sum of non-pegylated and pegylated
G-CSF free circulating (serum) concentrations; R: G-CSF receptors on circulating neutrophils; G-CSF: free circulating G-CSF concentration resulting from
endogenous production or from an administration of filgrastim/lenograstim; peg-GCSF: free circulating G-CSF concentration resulting from an administration
of pegfilgrastim; RC: bound non-pegylated and pegylated G-CSF assumed here to be pharmacologicaly inactive; kon/koff: on/off-rate constants with dissociation
constant KD=koff/kon; ka1(2): absorption rate constant for filgrastim/lenograstim (pegfilgrastim); kGCSF: zero-order rate constant of endogenous G-CSF
production; kel1: rate constant for the linear, non-specific elimination of endogenous G-CSF and filgrastim/lenograstim; kel2: rate constant for the linear,
non-specific elimination of pegfilgrastim; kint: rate constant for non-pegylated or pegylated G-CSF elimination after binding to receptors and internalization;
Emax1(Emax2): maximal effect of non-pegylated or pegylated G-CSF on progenitor proliferation (precursor maturation); EC501(EC502): free non-pegylated or
pegylated G-CSF concentration eliciting 50% of the maximal effect.
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from the systemic blood circulation compartment with a rate
constant, kcirc, representing the random movement of cells
into the tissue (15). In Friberg’s model, the rate constant of
transfer between the transit compartments, k, was defined as
(n+1)/MTT where n is the number of transit compartments
and MTT is the mean transit time or mean maturation time;
also, kcirc was assumed equal to k (17).
The only difference with Friberg’s model lies in the way the
regulation of the system by endogenous growth factors, i.e.,
G-CSF, is modeled. In Friberg’s model (15) and its variants
(18), the negative feedback on proliferation/maturation rates
from the circulating neutrophil counts was described using an
empirical function of ANC related to baseline levels. In the
present case, we chose a more physiological approach based
on circulating G-CSF concentrations. Since no measurements
of G-CSF concentrations were available in our study, we used
prior information contained in the model developed by
Krzyzanski et al. (32) for the disposition of endogenous G-
CSF and filgrastim and their effects on bone marrow pro-
genitors and precursors in healthy volunteers. In the model of
Krzyzanski et al. (32), the pharmacokinetics of free circulating
endogenous G-CSF was described by a one-compartment
model with zero-order input kGCSF (to mimic the endogenous
production of G-CSF) and two mechanisms of elimination: a
linear and a non-linear elimination. More precisely, free G-
CSF could either be eliminated by the kidneys (with first-order
rate constant kel) or could bind to receptors R present on
circulating neutrophils and bone marrow precursors (with
dissociation constant KD), followed by an internalization and
degradation (rate constant kint). In that model, it was assumed
that the G-CSF receptor complex, denoted RC, was pharma-
cologically inactive and that the circulating free G-CSF con-
centration was the driving force for the effects on stem cells
proliferation and maturation. Standard Emax models were
used for these effects, with two different Emax parameters for
proliferation and maturation, noted respectively Emax1 and
Emax2, and a single (common) potency parameter EC50. In
the case of filgrastim administration by the subcutaneous
route, an absorption compartment was used with a first-
order absorption rate constant ka.
In our clinical studies, patients not only received filgrastim
but could also receive lenograstim or pegfilgrastim. Identical
pharmacokinetic parameters were assumed for filgrastim and
lenograstim which are both recombinant forms of endogenous
G-CSF and immediate-release daily formulations. Note that
filgrastim and lenograstim show the same clinical efficacy at
the same dosage (8). Concerning pegfilgrastim, the pegylation
results in major differences in the pharmacokinetics with a
different absorption rate constant, a different apparent volume
of distribution (VDa) and, more importantly, a much reduced
renal elimination (12,29,33). To account for these differences
in pharmacokinetics, different sets of pharmacokinetic param-
eters were used for pegfilgrastim and filgrastim/lenograstim
with separate absorption and central compartments. In both
cases, values of ka, VDa and kel were taken from the literature.
Concerning filgrastim/lenograstim, they were denoted ka1,
VDa1 and kel1 and fixed to the previously published values
in Krzyzanski et al. (32). In the case of pegfilgrastim, they were
denoted ka2, VDa2 and kel2. The values of ka2 and VDa2 were
taken from Roskos et al. (29) while kel2 was fixed to 20% of kel1
based on the modeling work of Scholz et al. in man (33).
With respect to the neutrophil-mediated elimination, the
same binding and internalization parameters were used for
pegylated and non-pegylated G-CSF. Indeed, although the
binding to G-CSF receptor is weaker for filgrastim than for
pegfilgrastim, this difference is claimed to be marginal (36).
We also had to assume similar EC50 and Emax for pegylated
and non-pegylated G-CSF. Thus, in our model, the effects
on the bone marrow were mediated by the sum of unbound
circulating concentrations of non-pegylated G-CSF (corre-
sponding to filgrastim, lenograstim and endogenously pro-
duced G-CSF) and pegylated G-CSF (corresponding to
pegfilgrastim).
Different models were tested to describe the cytotoxic effect
of carboplatin on proliferative cells, assuming a linear drug
effect with a Slope parameter. The observed neutrophil data
were log-transformed before the analysis, and an additive
error model was used to model residual variability. A log-
normal distribution of individual PK/PD parameters was
assumed. The first-order conditional estimation (FOCE)
method in NONMEM 7.2 was used for the estimation of
the model parameters. Model development was guided by
the objective function value, precision in parameter estimates,
graphical assessment and visual predictive checks. The likeli-
hood ratio test was applied to differentiate between two nested
models at a significance level α=0.05.
Clinical knowledge about the factors that could impact
G-CSF prescription (EORTC guidelines (4,8,37)) was used to
preselect covariates: age, sex, corticosteroid multiple (> 4 days)
administration, monochemotherapy versus polychemotherapy,
monochemotherapy versus association with other cytotoxic
drugs (paclitaxel, etoposide, gemcitabine, or others), previous
chemotherapy, performance status, and comorbidities. The
relationship between preselected covariates and the predictions
of individual PK/PD parameters were investigated graphically.
The covariates for which a relationship was found were then
tested in NONMEM using a forward/backward strategy
(p-values<0.05 and 0.001, respectively).
Evaluation of the Final PK/PD Model
Standard goodness-of-fit plots were performed at each step
of the model building. The final model was evaluated
through visual predictive checks which compare observa-
tions with their predictive distribution under the model. Five
hundred replicates of the study design were simulated with
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the final model to produce visual predictive checks. Times of
ANC measurements were categorized into 15 bins, and
medians and 90% prediction intervals were calculated from
the observations and each of the simulated data set within
each bin. From the 500 simulated data sets, 95% confidence
intervals were then derived from the computed medians and
90% prediction intervals within each bin. These 95% confi-
dence intervals were plotted against time and superimposed
on the observations and the percentiles derived from these
observations. Finally, normalized prediction distribution er-
rors (NPDE (38)) were computed and their normality
assessed through a Quantile-Quantile plot and a histogram.
Simulation-Based Evaluation of the Individual
Response to G-CSF
A series of simulations were performed at the individual level
to understand the effect of G-CSF administration upon
ANC-time profile compared to the absence of G-CSF treat-
ment. More precisely, the model was applied to patients that
received G-CSF in our study to predict what would have
been their ANC time profile in the absence of G-CSF treat-
ment (based on their Empirical Bayes Estimates, i.e., the
predictions of individual PK/PD parameters).
In a second time, the influence of G-CSF formulation
was investigated. More specifically, we compared the
effect of filgrastim given subcutaneously on day 1 for 11 days
(5 μg/kg/day) with a single administration of pegfilgrastim
(6 mg) given subcutaneously on day 1. All these simulations
were performed in a mean patient, that is to say model
parameters were set to the population mean estimates.
Carboplatin was given on the first day of the first cycle and
the dose of carboplatin administered was set to the average
dose given to the patients in our study (545 mg). Carboplatin
individual PK parameters were set to the average of individual
PK parameter predictions.
RESULTS
Final Population PK/PD Model
When the model for G-CSF taken from Krzyzanski et al. (32)
was implemented as is, our PK/PD model did not provide a
very good description of the data. This is the reason why we
brought two modifications. The first modification, which led
to a considerable improvement in data fitting, was to set the
amount of G-CSF receptors involved in the specific elimina-
tion of G-CSF (Rmax) proportional to ANC and not to the
sum of ANC plus the amount of bone marrow precursors as
in the original model (32). This modification of the model
was supported by previous work showing that ANC drive
free G-CSF elimination from the bloodstream and, more
generally, drive G-CSF pharmacokinetics during the chemo-
therapy (39–41). The rational for this new model is discussed
in details in the discussion part of the article.
The second modification brought to the model was to
estimate distinct EC501 and EC502 parameters instead of a
single potency parameter. Regarding carboplatin toxicity,
carboplatin was assumed to induce a cell loss from the stem
cell compartment. The drug effect was proportional to the
ultrafiltrable-plasma concentration Ccarbo with the Slope param-
eter representing the sensitivity to carboplatin myelotoxicity.
To summarize, fixed effect parameters were estimated for
Base, θMTT 0 , Slope, Emax2, EC501 and EC502. As detailed in
Supplementary Material 2, we called MTT0 the MTT at
baseline, i.e., before any treatment, and MTT0 was
expressed as θMTT 0= 1þ Emax2 Cu0= EC502þ Cu0ð Þð Þ
where Cu0 is the free circulating G-CSF concentration at
baseline. Note that Emax1 (maximal effect of G-CSF on
proliferation) was difficult to estimate from the data and
was fixed to the previous estimate from Krzyzanski’s (32)
model. Other model parameters were fixed to the previously
published values as detailed in Table II. The system of
differential equations corresponding to our final model with
the specification of initial conditions is available in Supple-
mentary Material 2. Moderate interindividual variability
was estimated for Base (30%), θMTT 0 (21%), and Slope
(22%). The intra-patient variability between cycle 1 and
cycle 2, also called inter-occasion variability, could also be
estimated for Slope. Only one significant covariate was iden-
tified for baseline ANC (Base): multiple corticosteroid admin-
istration (yes/no), with an average increase in baseline ANC
of 25% in case of multiple corticosteroid administration.
Final model parameter estimates are given in Table II.
The final model was evaluated with standard goodness-of-fit
plots (observed vs. individual predicted ANC and observed vs.
population ANC plots) and visual predictive checks, all
displayed in Fig. 3. Standard goodness-of-fit plots look ade-
quate despite a tendency of the model to overestimate low
ANC values or, in other terms, underestimate the cytotoxicity
of carboplatin. Visual predictive checks show, however, that the
model was able to capture the median time-course of the ANC
for the two subgroups of patients (with or without G-CSF) even
though one median observation was slightly below its 95%
confidence interval for patients off G-CSF around the nadir
of the second cycle. Note that model-based confidence intervals
were larger for patients on G-CSF due to the lower number of
patients in that group (N=47). Overall, the interindividual
variability was well described by the model. Indeed, although
some of the 5th percentiles for observations were above their
95% confidence interval for patients off G-CSF between 17
and 27 days, the visual predicted checks show the ability of the
model to describe and predict the nadir value of neutrophils in
both groups of patients, which is of major interest from a
clinical point of view. The plots of normalized prediction
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distribution errors, NPDE, indicated no major departure from
the standard normal distribution, showing that the model
looked reasonable (plots not shown).
Individual predicted time-profiles of free circulating G-
CSF concentrations are presented in Fig. 4 for patients off G-
CSF. Indeed, although there is no interindividual variability
for G-CSF PK parameters, the clearance of G-CSF depends
on ANC and that introduces the variability to the individual
free G-CSF concentrations. Individual predictions of ANC-
time profiles are also displayed in Fig. 4 to highlight how free
circulating G-CSF concentrations are inversely correlated
with ANC.
Simulation-Based Evaluation of Individual Response
to G-CSF
For the comparison of pegylated and daily formulations, the
simulations reveal a longer and stronger effect for pegfilgrastim
than for filgrastim even when the latter is given for 11 consec-
utive days (Fig. 5b and c). Remind that G-CSF increases
proliferation rate and transit rate and it is important to assess
the difference over time between these rates to understand the
difference in neutrophil time-course between the two formu-
lations. As can be seen on Fig. 5f, the difference in profiles
between proliferation and transit rates is very small for
filgrastim: they reach immediately the same plateau level
and, when treatment is stopped, they both decrease very
rapidly to baseline levels because of the very high clearance
of free G-CSF. On the contrary, when pegfilgrastim is admin-
istered, the decrease in free circulating G-CSF concentration is
much slower due to a much lower renal clearance resulting
from the pegylation. Given the lower EC50 for proliferation
(EC501) than for maturation (EC502), it follows that the rate of
proliferation exceeds the rate of transit time during the termi-
nal phase of pegfilgrastim pharmacokinetics (Fig. 5e). This
difference would explain the stronger and faster rebound
after pegfilgrastim administration than after filgrastim
treatment.
Finally, the simulations predicting what would have been
the ANC time-profile without G-CSF for patients receiving
G-CSF in our study support the idea that G-CSF was not
beneficial in all situations. Three chosen patients are shown
Table II Final Covariate Model
Model Parameters Value [RSE%] IIV [RSE%]
PK-PD estimated parameters Base=θ1×(1−CORT)+θ2×CORT θ1=4.88×10
9/L [2.6%] 30% [12%]
CORT = 0 or 1 θ2=6.13×10
9/L [4.3%]
θMTT0 ¼ θ3 θ3=185 h [4.2%] 21% [20%]
Slope = θ5 θ5=0.0161 [3.9%] L/(mg.h) 22% [56%]
IOV=34% [19%]
Emax2 = θ6 θ6=3.73 [17%] –
EC501 = θ7 θ7=0.0763 ng/mL [14%] –
EC502 = θ8 θ8=0.402 ng/mL [15%] –
Residual variability 52.1% [2.1%] –
PK parameters of G-CSF (fixed as in (29), (32) and (33)) ka1 0.0228 h
−1
–
ka2 0.651 h
−1
–
VDa1 5.07 L –
VDa2 4.02 L –
kint 0.105 h
−1
–
kel1 0.152 h
−1
–
kel2 0.2 × kel1 h
−1 –
kD 1.44 ng/mL –
ξ 0.181 fg/cell –
Emax1 34.7 –
RSE relative standard error expressed in %, IIV interindividual variability, IOV intraindividual (interoccasion) variability, Base baseline level of absolute neutrophil
count, CORT 1 means that the patients received multiple administration of corticosteroids (> 4 days) (CORT= 0 otherwise), θMTT0 population parameter for
mean transit time at baseline (MTT0) such that MTT0 ¼ θMTT0=H20 where H20 is the Hill function for the effect of free G-CSF on maturation rate (see
Supplementary Material 2 for more details), Slope sensitivity to carboplatin cytotoxicity, Emax1(2) maximal effect of G-CSF on proliferation (maturation),
EC501(2) free G-CSF concentration eliciting 50% of the maximal effect on proliferation (maturation), ka1(2) absorption rate constant for the daily (pegylated)
formulation, VDa1(2) apparent volume of distribution for the daily (pegylated) formulation, kint rate constant for non-pegylated and pegylated G-CSF
elimination after binding to receptors and internalization, kel1 rate constant for the linear, non-specific elimination of endogenous G-CSF and filgrastim/
lenograstim, kel2 rate constant for the linear, non-specific elimination of pegfilgrastim, KD dissociation constant of RC complex, ξ proportionality constant for the
amount of G-CSF receptors per cell
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in Fig. 6, illustrating three possible scenarios. For one pa-
tient, G-CSF shows some clear benefit, preventing high
grade neutropenia at the second cycle. In the second and
third patients, G-CSF treatment does not allow any
improvement in ANC time-profile with respect to low
ANC values and the nadir can even be slightly worse.
DISCUSSION
The population PK/PD model presented here was able to
correctly describe ANC time course in 375 patients with
various tumors treated with carboplatin, whether or not they
received G-CSF during their chemotherapy. This model
appears more physiological than previously published con-
ventional models (see (14–16) for reviews) because it allows a
description of both endogenous and exogenous G-CSF and
its effect on the proliferation and maturation of progenitors
and precursors in the bone marrow. The power function (γ)
in Friberg’s model (17), representing the negative feedback
on the production of mature neutrophils, was replaced by a
more physiological representation of endogenous and exog-
enous G-CSF effects on the proliferation and maturation
rates.
The model of Krzyzanski et al. (32) was used as prior
information for the disposition and PK/PD of endogenous
and exogenous G-CSF. However, a major modification was
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bFig. 3 Top: Goodness-of-fit plotsfor observations vs. a) individual
predictions and b) population
predictions of absolute neutrophil
counts (ANC). Bottom: Visual
predictive checks for ANC (.109/
L) for the final model based on
500 simulations of the study
design in c) patients off G-CSF and
d) patients receiving G-CSF at
least once. The circles represent
the observed data. The solid lines
refer to the median, 5th and 95th
percentiles of the observed data.
Shaded areas are the 95%
confidence intervals for the
median and percentiles 5th and
95th under the model.
Fig. 4 Individual predicted time-profiles of free circulating G-CSF concen-
trations and ANC for patients off G-CSF. Note that free circulating G-CSF
concentrations are inversely correlated with ANC.
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brought to this model driven by a much better data fitting.
This modification was to set the nonlinear component of
G-CSG clearance proportional to ANC and not to the sum of
ANC and precursor cell counts as in (32). The time course of
ANC under chemotherapy was not the same as the time
course of precursor cell counts in the bone marrow compart-
ments, and this difference was certainly discriminating in the
selection of such a model. The work of Quartino et al. showed
indeed mirror patterns for the variations of ANC and endog-
enous G-CSF serum concentrations over time for cancer
patients off G-CSF therapy (18).
Note that the assumption of proportionality between
ANC and the nonlinear component of G-CSF clearance
has also been made by others (24,29,31). However, the
rational for such proportionality is unclear. It has been
shown that the amount of G-CSF receptors per cell increases
with the maturation and is the highest in circulating
neutrophils (42–44). On the other hand, the total pool of
G-CSF receptors in the bone marrow needs to be consid-
ered. By setting Rmax (pool of receptors involved in G-CSF
elimination) proportional to ANC only, the risk is thus to
underestimate G-CSF nonlinear clearance. We therefore
tried to compensate for this possible underestimation by re-
estimating ξ (the amount of G-CSF receptors per cell) and
obtained a higher value (5.91 fg/cell) than in Krzyzanski et al.
(32), i.e., 0.181 fg/cell. The problem is that the resulting
model led to predictions that were not very plausible: espe-
cially, it predicted an abnormally high proportion of neutro-
penia events in patients off G-CSF and almost no prophylactic
effect of (peg)filgrastim. These unexpected results shed light on
the potential limitations of the structural model of G-CSF
itself. In this model, the effect of G-CSF on the bone marrow
is driven by the unbound G-CSF concentration Cu. In other
terms, what is eliminated by internalization after binding to
9 99
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Fig. 5 Effects of subcutaneous pegylated (b, e [6 mg at day 1]) and daily formulations (c, f [5 μg/kg/day at day 1 for 11 days]) compared to the absence of G-
CSF (a, d) administration in a mean patient. More precisely, we compared the effect of G-CSF formulation (i) on the time-course of proliferative cells
(compartment Prol) and circulating neutrophils (compartment Circ) and (ii) on the time-course of proliferation rate (calculated as kprol  1þ Emax1CuEC501þCu
 
) and
maturation rate (calculated as ktr  1þ Emax2CuEC502þCu
 
and corresponding to k). In each case, 545 mg of carboplatin were administered at day 0. (a, b and c)
Dashed lines correspond to proliferative cell count in bone marrow (compartment Prol) and the solid lines to the ANC. (d, e and f) Black lines correspond to
the effect of G-CSF (endogenous and exogenous) on proliferation rate and the grey lines to the effect on maturation (transit) rate.
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G-CSF receptors has no effect. While this is true for blood
(receptors on ANC are considered as pharmacologically inac-
tive), this is not true for the bone marrow. A more relevant
model would be to model the effect as a function of the
fraction bound to bone marrow receptors and not as a func-
tion of Cu as in classical PK/PD models. We did not have the
data to build such amodel and thus kept the original value of ξ
(0.181 fg/cell) given by Krzyzanski et al. (32). As discussed by
the authors themselves, this value (equivalent to 5824
molecules/cell) is higher than the number of receptors per
neutrophil found in the literature (30).
Clearly, the main limitation of our work is the lack of G-
CSF concentration data and the assumption that G-CSF
pharmacokinetic parameters were identical in healthy vol-
unteers and cancer patients. It is likely that cancer patients
receiving carboplatin may suffer from renal insufficiency
since carboplatin is administered in place of cisplatin which
cannot be administered to renally impaired patients. Thus, a
smaller renal clearance may be encountered in cancer pa-
tients treated with carboplatin, resulting in higher G-CSF
circulating concentrations and possibly in different nadir
values. On the other hand, a sensitivity analysis (not shown)
showed the little influence of the first-order rate constant for
renal elimination (kel) on nadir values. It is noteworthy that
for pegfilgrastim, the renal elimination is very minor, with no
change in serum concentration-time profiles among subjects
with various degrees of renal impairment (45).
The model of Krzyzanski et al. (32) was originally built
for endogenous G-CSF and filgrastim. In the present
work, it was extended to describe the effect of pegfilgrastim
which was administered to some of the patients in our clinical
study. Different sets of pharmacokinetic parameters were
used for pegfilgrastim to account for the difference in phar-
macokinetics between pegylated and non-pegylated G-CSF.
Pegfilgrastim pharmacokinetic parameters were taken
from the literature (29,33). Especially, the first-order rate
constant for unspecific renal elimination (kel2) was fixed to
20% of the one for filgrastim (kel1) based on the modeling
work of Scholz et al. in man (33). A difference of the same
order of magnitude was observed in the rat: the linear com-
ponent of pegfilgrastim clearance was 90% lower than for
filgrastim (12).
Despite these limitations, our final model gave reasonable
predictions in terms of neutropenia events and (peg)filgrastim
effects and well described our clinical data. Efficacy and
potency parameters were re-estimated, except for Emax1
(maximal effect on proliferation rate) due to estimability issues.
In contrast to the original model for G-CSF (32), two distinct
EC501 and EC502 parameters were estimated.
Simulation studies were then performed to understand the
differences in G-CSF effects and explore the impact of G-CSF
formulation. The most surprising finding in these simulation
studies was that G-CSF was not as beneficial as expected
in some patients with respect to nadir values. It is well
established that G-CSF reduces the maturation time of bone
marrow precursors (6,7) and that cytotoxic drugs like
carboplatin induce a cell loss from the proliferation compart-
ment (see review (46)). Consequently, it is possible that a
9
Pegfilgrastim
9 9
Lenograstim 8 days
Lenograstim 9 days
a b c
Fig. 6 Prediction of the ANC time-profile without G-CSF for 3 patients who received G-CSF treatment in our data set. The circles correspond to the
observations, the solid line to the individual predictions under G-CSF treatment and the dashed line to the individual predictions off G-CSF treatment.
Carboplatin administrations are indicated by vertical arrows on the x-axis. (a) Patient who clearly shows benefit from G-CSF treatment. Carboplatin was given
at day 0 (583 mg) and day 21 (555 mg), while pegfilgrastim (6 mg) was given subcutaneously at day 1 and day 22. (b and c) Patients for whom G-CSF
treatment does not allow any improvement in the nadir. For patient (b), carboplatin was given at day 0 (660 mg) and day 36 (520 mg); lenograstim (5 μg/kg/
day) was administered subcutaneously at day 36 for 9 consecutive days. For patient (c), carboplatin was given at day 0 (608 mg) and day 21 (506 mg);
lenograstim (5 μg/kg/day) was administered subcutaneously at day 5 and day 26 for 8 consecutive days.
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temporary depletion of stem cell pool occurs after administra-
tion of anticancer drug concomitant with or followed by G-
CSF administration. Such depletion might be problem-
atic in some patients. Additionally, our simulation studies
suggest that one administration of pegfilgrastim would be
more effective than 11 consecutive administrations of
filgrastim. This is consistent with recent publications
(4,5,10,11), even if other publications did not evidence any
difference between the formulations. A large interindividual
variability, leading to low powerful studies, could explain such
discrepancies.
Even if our model appears more physiological for the
reasons explained above, the increase in model complexity
was limited by the available data. Especially, it would have
been of interest to include an additional compartment for
quiescent cells among progenitor cells (cells in G0 phase). For
some patients, this compartment could act as a storage pool
of mitotic cells that would limit the depletion of the bone
marrow due to the acceleration of the transit time under G-
CSF treatment. For other patients, this pool would not be
sufficient enough to avoid this depletion. Unfortunately, the
available data did not allow such model to be implemented
and estimated.
CONCLUSION
The proposedmodel allows a mechanistic interpretation of G-
CSF effects on ANC in carboplatin-treated cancer patients.
Especially, it raises the question of a systematic beneficial
effect of G-CSF treatment (pegfilgrastim, filgrastim). In other
words, some cancer patients do not appear to benefit from G-
CSF treatment and this could explain why G-CSF does not
prevent febrile neutropenia in all patients. Obviously, other
studies are needed to confirm these findings and help identi-
fying the patients for whom G-CSF would be beneficial.
Finally, our model suggests that pegfilgrastim gives a shorter
and weaker neutropenia than the daily formulations, and
should probably be preferred. It is clear that our model relies
on previous knowledge and assumptions that need to be
further documented. However, we believe that such physio-
logical model is the way to go to better understand and predict
G-CSF treatment effects in various situations.
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